Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin Against Streptococcus pneumoniae Using Data from a Neutropenic Murine-Lung Infection Model.

Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.02606-18. doi: 10.1128/AAC.02606-18. [Epub ahead of print]

PMID:
31182534
2.

Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies.

Bird ST, Swain RS, Tian F, Okusanya OO, Waldron P, Khurana M, Durmowicz EL, Ma Y, Major JM, Gelperin K.

Lancet Child Adolesc Health. 2019 Jan;3(1):15-22. doi: 10.1016/S2352-4642(18)30335-3. Epub 2018 Nov 17.

PMID:
30455109
3.

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.

Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb.

4.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

5.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.

Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.

6.

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.

Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R.

Antimicrob Agents Chemother. 2014 Sep;58(9):5005-15. doi: 10.1128/AAC.02421-13. Epub 2014 Mar 31.

7.

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.

8.

Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.

Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.

Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17.

9.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.

10.

Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.

Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jan;57(1):498-507. doi: 10.1128/AAC.01354-12. Epub 2012 Nov 12.

11.

Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.

Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1578-83. doi: 10.1128/AAC.05382-11. Epub 2011 Dec 12.

12.

Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.

Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S513-9. doi: 10.1093/cid/cir166.

PMID:
21546628
13.

Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection.

Okusanya OO, Tsuji BT, Bülitta JB, Forrest A, Bulik CC, Bhavnani SM, Fernandes P, Ambrose PG.

Diagn Microbiol Infect Dis. 2011 May;70(1):101-11. doi: 10.1016/j.diagmicrobio.2011.03.001.

PMID:
21513848
14.

Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.

Drusano GL, Okusanya OO, Okusanya AO, van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2009 Nov;53(11):4718-25. doi: 10.1128/AAC.00802-09. Epub 2009 Aug 17.

15.

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection.

Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R.

Antimicrob Agents Chemother. 2009 Sep;53(9):3847-54. doi: 10.1128/AAC.00872-08. Epub 2009 May 18.

16.

Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, Kulawy R, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2008 Nov;52(11):3973-9. doi: 10.1128/AAC.00453-08. Epub 2008 Aug 25.

17.

Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.

Ambrose PG, Anon JB, Bhavnani SM, Okusanya OO, Jones RN, Paglia MR, Kahn J, Drusano GL.

Diagn Microbiol Infect Dis. 2008 May;61(1):13-20. doi: 10.1016/j.diagmicrobio.2008.01.010. Epub 2008 Mar 3.

PMID:
18313879
18.

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, Forrest A, Morse GD.

Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):473-85. Review.

PMID:
16863456
19.

Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD.

Curr Pharm Des. 2006;12(9):1129-45. Review.

PMID:
16515491

Supplemental Content

Loading ...
Support Center